Filtered By:
Source: Oncotarget
Cancer: Melanoma

This page shows you your search results in order of date.

Order by Relevance | Date

Total 22 results found since Jan 2013.

Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior
Oncotarget. 2023 Mar 21;14:219-235. doi: 10.18632/oncotarget.28388.ABSTRACTGlypicans (GPC1-6) are associated with tumorigenic processes and their involvement in neoplastic behavior has been discussed in different cancer types. Here, a cancer-wide GPC expression study, using clinical cancer patient data in The Cancer Genome Atlas, reveals net upregulation of GPC1 and GPC2 in primary solid tumors, whereas GPC3, GPC5 and GPC6 display lowered expression pattern compared to normal tissues. Focusing on GPC1, survival analyses of the clinical cancer patient data reveal statistically significant correlation between high expression...
Source: Oncotarget - March 21, 2023 Category: Cancer & Oncology Authors: Fang Cheng Victor Ch érouvrier Hansson Grigorios Georgolopoulos Katrin Mani Source Type: research

Transducin-like enhancer of split 3 regulates proliferation of melanoma cells via histone deacetylase activity.
In conclusion, these data indicate that Tle3 is required, at least in part, for proliferation in the B16 mouse melanoma model. PMID: 30719233 [PubMed]
Source: Oncotarget - February 7, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression.
Authors: Yanagi T, Nagai K, Shimizu H, Matsuzawa SI Abstract Melanoma-associated antigen family A (MAGE-A) is a family of cancer/testis antigens that are expressed in malignant tumors but not in normal tissues other than the testes. MAGE-A12 is a MAGE-A family gene whose tumorigenic function in cancer cells remains unclear. Searches of the Oncomine and NextBio databases revealed that malignant tumors show up-regulation of MAGE-A12 mRNA relative to corresponding normal tissue. In PPC1 primary prostatic carcinoma cells and in HCT116 colorectal cancer cells (wild type and p53-depleted), MAGE-A12 gene knockdown using s...
Source: Oncotarget - August 7, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation.
Authors: Suleymanova N, Crudden C, Worrall C, Dricu A, Girnita A, Girnita L Abstract Due to its ability to compensate for signals lost following therapeutic MAPK-inhibition, insulin-like growth factor type 1 receptor (IGF-1R) co-targeting is a rational approach for melanoma treatment. However IGF-1R conformational changes associated with its inhibition can preferentially activate MAPK-pathway in a kinase-independent manner, through a process known as biased signaling. We explored the impact of biased IGF-1R signaling, on response to MAPK inhibition in a panel of skin melanoma cell lines with differing MAPK and p53 ...
Source: Oncotarget - July 29, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1.
In conclusion, our results demonstrate for the first time a direct activation of NRP-1 by PDGF-C and strongly suggest that autocrine and/or paracrine stimulation of NRP-1 by PDGF-C might contribute to the acquisition of a metastatic phenotype by melanoma cells. PMID: 28700345 [PubMed - as supplied by publisher]
Source: Oncotarget - July 14, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.
In this study, we analyzed genome-wide gene expression profiling data from 6 sensitive and 6 resistant cell lines to identify candidate genes whose expression changes are associated with responses to a MEK inhibitor, selumetinib (AZD6244). Of 62 identified differentially expressed genes, we selected Immunoglobulin Transcription Factor 2, also known as transcription factor 4 as a potential drug resistance marker for further analysis. This was because the ITF-2 expression increase in resistant cell lines was relatively high and a previous study has suggested that ITF-2 functions as an oncogene in human colon cancers. We also...
Source: Oncotarget - June 4, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma.
Authors: Liu F, Jiang CC, Yan XG, Tseng HY, Wang CY, Zhang YY, Yari H, La T, Farrelly M, Guo ST, Thorne RF, Jin L, Wang Q, Zhang XD Abstract The expression of CD47 on the cancer cell surface transmits "don't eat me" signalling that not only inhibits phagocytosis of cancer cells by phagocytes but also impairs anti-cancer T cell responses. Here we report that oncogenic activation of ERK plays an important role in transcriptional activation of CD47 through nuclear respiratory factor 1 (NRF-1) in melanoma cells. Treatment with BRAF/MEK inhibitors upregulated CD47 in cultured melanoma cells and fresh melanoma isolates. ...
Source: Oncotarget - May 26, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.
Authors: Basu R, Wu S, Kopchick JJ Abstract Recent reports have confirmed highest levels of growth hormone (GH) receptor (GHR) transcripts in melanoma, one of the most aggressive forms of human cancer. Yet the mechanism of GH action in melanoma remains mostly unknown. Here, using human malignant melanoma cells, we examined the effects of GH excess or siRNA mediated GHR knock-down (GHRKD) on tumor proliferation, migration and invasion. GH promoted melanoma progression while GHRKD attenuated the same. Western blot analysis revealed drastic modulation of multiple oncogenic signaling pathways (JAK2, STAT1, STAT3, STAT5...
Source: Oncotarget - February 24, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Authors: Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF Abstract Activating mutations in the KRAS and BRAF genes, leading to hyperactivation of the RAS/RAF/MAPK oncogenic signaling cascade, are common in patients with colorectal cancer (CRC). While selective BRAF inhibitors are efficacious in BRAFmut melanoma, they have limited efficacy in BRAFmut CRC patients. In a RASmut background, selective BRAF inhibitors are contraindicated due to paradoxical activation of the MAPK pathway through potentiation of CRAF kinase activity. A way to ...
Source: Oncotarget - December 23, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

HSPB1 deficiency sensitizes melanoma cells to hyperthermia induced cell death.
Authors: Wang HX, Yang Y, Guo H, Hou DD, Zheng S, Hong YX, Cai YF, Huo W, Qi RQ, Zhang L, Chen HD, Gao XH Abstract Hyperthermia has shown clinical potency as a single agent or as adjuvant to other therapies in cancer treatment. However, thermotolerance induced by thermosensitive genes such as the heat shock proteins can limit the efficacy of hyperthermic treatment. In the present study, we identified HSPB1 (HSP27) is hyperthermically inducible or endogenously highly expressed in both murine and human melanoma cell lines. We used a siRNA strategy to reduce HSPB1 levels and showed increased intolerance to hyperthermi...
Source: Oncotarget - September 15, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.
Authors: Nihal M, Wood GS Abstract Melanoma is one of the most aggressive and lethal forms of skin cancer. Despite recent improvements in targeted therapies, many patients with advanced disease fail to achieve lasting tumor regression. Therefore, it is important to develop novel druggable targets that can be exploited to improve clinical outcome. Here, we studied the role of Casitas B-lineage lymphoma (c-CBL), an E3 ubiquitin ligase, in human melanoma. Employing quantitative real-time PCR and Western blot analysis in a panel of human melanoma cell lines (A375, G361, Hs-294T, SK-Mel-2, SK-Mel-28 and 451Lu), we found...
Source: Oncotarget - July 30, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma.
Authors: Alver TN, Lavelle TJ, Longva AS, Øy GF, Hovig E, Bøe SL Abstract The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway is frequently hyper-activated upon vemurafenib treatment of melanoma. We have here investigated the relationship between SRY-box 10 (SOX10), forkhead box 3 (FOXD3) and microphthalmia-associated transcription factor (MITF) in the regulation of the receptor tyrosine-protein kinase ERBB3, and its cognate ligand neuregulin 1-beta (NRG1-beta). We found that both NRG1-beta and ERBB3 mRNA levels were elevated as a consequence of MITF depletion, induced by either vemurafenib or MITF ...
Source: Oncotarget - July 9, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells.
This study confirms the prognostic potential of SERPINA3 expression in human cutaneous melanoma and reveals the pro-migration and pro-invasion functions of this protein on melanoma cells. PMID: 27213583 [PubMed - as supplied by publisher]
Source: Oncotarget - May 24, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research